TY - JOUR
T1 - Epitope Mapping of Monoclonal Antibody PMab-52 Against Cat Podoplanin
AU - Chang, Yao Wen
AU - Kaneko, Mika K.
AU - Yamada, Shinji
AU - Kato, Yukinari
N1 - Funding Information:
Y.K. received research funding from Ono Pharmaceutical Co., Ltd. All other authors have nothing to disclose.
Funding Information:
This research was supported in part by AMED under Grant Numbers: JP17am0301010 (Y.K.), JP17am0101078 (Y.K.), and JP17ae0101028 (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and Grant Number 16K10748 (Y.K.). This work was performed in part under the Cooperative Research Program of Institute for Protein Research, Osaka University, CR-17-05 and by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo.
Funding Information:
This research was supported in part by AMED under Grant Numbers: JP17am0301010 (Y.K.), JP17am0101078 (Y.K.), and JP17ae0101028 (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and Grant Number 16K10748 (Y.K.). This work was performed in part under the Cooperative Research Programof Institute for ProteinResearch,OsakaUniversity,CR- 17-05 and by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc. 2018.
PY - 2018/4
Y1 - 2018/4
N2 - The mucin-type membrane glycoprotein podoplanin (PDPN) is frequently overexpressed in numerous malignant cancers, including squamous cell carcinoma, germinal neoplasia, mesothelioma, lung cancer, oral cancer, and brain tumor. PDPN expression is strongly associated with cancer progression and poor prognosis. Furthermore, PDPN binds to C-type lectin-like receptor 2 (CLEC-2) on platelets, followed by PDPN-mediated platelet aggregation to facilitate tumor metastasis. We have previously reported a novel anti-cat PDPN (cPDPN) monoclonal antibody (mAb), PMab-52, which specifically detects cPDPN using flow cytometry analysis and successfully identifies cPDPN in feline squamous cell carcinomas. However, the specific binding epitope of cPDPN for PMab-52 remains unelucidated. In this study, a series of deletion or point mutants of cPDPN were utilized for investigating the binding epitopes of PMab-52 using flow cytometry and Western blotting. The findings of this study revealed that the critical epitopes of platelet aggregation-stimulating domain 4 (PLAG4) of cPDPN are responsible for the binding of PMab-52 to cPDPN.
AB - The mucin-type membrane glycoprotein podoplanin (PDPN) is frequently overexpressed in numerous malignant cancers, including squamous cell carcinoma, germinal neoplasia, mesothelioma, lung cancer, oral cancer, and brain tumor. PDPN expression is strongly associated with cancer progression and poor prognosis. Furthermore, PDPN binds to C-type lectin-like receptor 2 (CLEC-2) on platelets, followed by PDPN-mediated platelet aggregation to facilitate tumor metastasis. We have previously reported a novel anti-cat PDPN (cPDPN) monoclonal antibody (mAb), PMab-52, which specifically detects cPDPN using flow cytometry analysis and successfully identifies cPDPN in feline squamous cell carcinomas. However, the specific binding epitope of cPDPN for PMab-52 remains unelucidated. In this study, a series of deletion or point mutants of cPDPN were utilized for investigating the binding epitopes of PMab-52 using flow cytometry and Western blotting. The findings of this study revealed that the critical epitopes of platelet aggregation-stimulating domain 4 (PLAG4) of cPDPN are responsible for the binding of PMab-52 to cPDPN.
KW - Cat podoplanin
KW - Epitope
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85046252242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046252242&partnerID=8YFLogxK
U2 - 10.1089/mab.2017.0067
DO - 10.1089/mab.2017.0067
M3 - Article
C2 - 29394131
AN - SCOPUS:85046252242
VL - 37
SP - 95
EP - 99
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
SN - 2167-9436
IS - 2
ER -
